Manidipino Kern Pharma (Manidipine Dihydrochloride)

Manidipine is a dihydropyridine calcium‑channel blocker used primarily to manage elevated arterial pressure.

• Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular complications.
• Essential hypertension: provides sustained blood‑pressure control when lifestyle measures are insufficient.
• Primary hypertension: improves overall vascular resistance and cardiac workload.

• Manidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that leads to muscle contraction. This vasodilatory effect reduces peripheral vascular resistance, resulting in a decrease in systemic blood pressure without significant direct cardiac depression.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity, often occurring early in therapy.
• Flushing: sensation of warmth and redness, especially in the face.
• Peripheral edema: swelling of ankles or lower legs due to fluid accumulation.
• Dizziness or light‑headedness, particularly after standing.
• Tachycardia: increased heart rate as a reflex response.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Angioedema: swelling of lips, tongue, or airway requiring urgent care.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic injury: abnormal liver function tests or hepatitis.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Before initiating therapy with Manidipine, several safety considerations should be reviewed.

• Blood pressure monitoring: measure baseline and periodic readings to avoid excessive hypotension.
• Renal impairment: adjust therapy cautiously in patients with reduced kidney function.
• Hepatic impairment: use with care in liver disease due to altered metabolism.
• Concomitant antihypertensives: assess risk of additive blood‑pressure lowering effects.
• Pregnancy and lactation: avoid unless benefits clearly outweigh potential risks.
• Elderly patients: start at lower doses and monitor for orthostatic symptoms.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Other calcium‑channel blockers: additive vasodilatory effect can cause severe hypotension.
• Nitrates: combined use may lead to profound blood‑pressure drops.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia or heart‑block phenomena.

• Diuretics: increased risk of electrolyte imbalance and hypotension.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.